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Purpose: To determine the diagnostic yield and clinical impact of
exome sequencing (ES) in patients with suspected monogenic
kidney disease.
Methods: We performed clinically accredited singleton ES in a
prospectively ascertained cohort of 204 patients assessed in
multidisciplinary renal genetics clinics at four tertiary hospitals in
Melbourne, Australia.
Results: ES identified a molecular diagnosis in 80 (39%) patients,
encompassing 35 distinct genetic disorders. Younger age at
presentation was independently associated with an ES diagnosis
(p < 0.001). Of those diagnosed, 31/80 (39%) had a change in their
clinical diagnosis. ES diagnosis was considered to have contributed
to management in 47/80 (59%), including negating the need for
diagnostic renal biopsy in 10/80 (13%), changing surveillance in 35/
80 (44%), and changing the treatment plan in 16/80 (20%). In cases
with no change to management in the proband, the ES result had
implications for the management of family members in 26/33
(79%). Cascade testing was subsequently offered to 40/80
families (50%).
Conclusion: In this pragmatic pediatric and adult cohort with
suspected monogenic kidney disease, ES had high diagnostic and
clinical utility. Our findings, including predictors of positive
diagnosis, can be used to guide clinical practice and health service
design.
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INTRODUCTION
Chronic kidney disease (CKD) affects more than 10% of the
adult population and causes substantial morbidity and
mortality, primarily related to the increased risk of cardio-
vascular disease.1 Genetic kidney disease (GKD) is increas-
ingly recognized as an important cause of CKD and can be
difficult to accurately diagnose using traditional diagnostic
strategies.2 Genomic studies have provided estimates of the
prevalence of GKD, demonstrating a diagnostic yield of
almost 10% in unselected adults3 and 20–30% in children with
nephropathy.4,5 The clinical application of genomic technol-
ogies has the potential to transform diagnostic pathways by
providing a timely and accurate genetic diagnosis.6 In patients
with GKD, this has several potential benefits, including
providing prognostic information, informing targeted surveil-
lance and therapies,7–9 preventing inappropriate treatments,10
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informing reproductive decisions, and reducing the use of
invasive diagnostic investigations such as renal biopsies.
Genomic testing is becoming established as a powerful
diagnostic tool in pediatric rare disease, and evidence that
genomic testing informs clinical decisions is beginning to
emerge in this context.11,12 To inform implementation across
other specialties, such as nephrology, it is important to
specifically evaluate the diagnostic and clinical utility of
genomic tests in relevant patient groups and real-world
contexts. The largest study of genomic testing in renal
patients to date reported a diagnostic yield of just under 10%
in an unselected cohort.3 The study was research-based, with
only broad categories and diagnostic codes available in terms
of phenotypic data for a substantial proportion of patients.
Results were not returned to patients, and hence the clinical
value of genomic testing, both to the patient and their family,
was not evaluated. A small number of studies have provided
retrospective or pilot single-center evaluations of clinical
genomic tests in renal patients13,14 or evaluated research-
based genomic tests in particular subgroups of kidney disease
such as transplant recipients or steroid-resistant nephrotic
syndrome.4,15 This preliminary evidence supports the value of
exome sequencing (ES) in both adult and pediatric patients
with renal disease, paving the way for wider implementation.
Such broader implementation poses significant challenges,
particularly with regard to developing evidence-based guide-
lines for patient triage and testing, as well as the development
of service delivery models that enable timely access to genetic
counseling, specialists, and testing services. Renal genetics
clinics (RGC) are one model of addressing these challenges.
RGCs apply a multidisciplinary team (MDT) approach
through collaboration between adult and pediatric nephrol-
ogists, clinical geneticists, genetic counselors, and laboratory
scientists. Preliminary evidence has shown that dedicated
RGCs may improve diagnostic outcomes and enhance care of
patients.14,16,17
We sought to determine the diagnostic yield and clinical
impact on patients and their families of clinically accredited
ES in a prospective cohort of adults and children with
suspected genetic kidney disease in the context of a
multidisciplinary RGC.
MATERIALS AND METHODS
Ethics statement
This study was approved by the Human Research Ethics
Committee at Melbourne Health (2016.224) and site-specific
research governance approval was obtained from all partici-
pating hospitals. All patients or their guardians provided
written informed consent for clinical ES and participation in
the study.
Study design
This prospective multicenter cohort study recruited patients
referred to one of four RGC teams based at tertiary hospitals
in Melbourne, Australia between July 2017 and September
2018, with data collected to October 2019. All reporting was
performed in accordance with the Strengthening the Report-
ing of Observational Studies in Epidemiology guidelines.18
Following referral by their treating nephrologist, patients
were discussed for study inclusion by the RGC team. Patients
were recruited if their clinical presentation was consistent
with a monogenic cause (e.g., glomerular, tubulointerstitial, or
cystic renal disease) and prioritized if they met one of the
following criteria: family history of renal disease, syndromic
features, or childhood onset of disease. Patients who did not
meet these criteria were considered at the discretion of the
MDT. Patients with phenotypes where the likelihood of a
monogenic cause is low, for example, congenital anomalies of
the kidney and urinary tract (CAKUT) were only included if
they had extrarenal features. Patients with a pre-existing
molecularly confirmed genetic diagnosis or a phenotype and
family history suggestive of typical autosomal dominant
polycystic kidney disease (ADPKD) were excluded.
Patients were reviewed in a multidisciplinary RGC setting
by a nephrologist, clinical geneticist, and genetic counselor on
at least two occasions (before and after testing). Chromosomal
microarray (CMA) was recommended in all patients prior to
ES to identify copy-number variants (CNVs). The workflow
from initial patient review to return of results is summarized
in Fig. 1.
Data collection
Detailed clinical and demographic data were collected and
entered into a secure REDCap19,20 electronic data capture tool
hosted at the Murdoch Children’s Research Institute.
Comprehensive phenotypic information was entered pro-
spectively by the nephrologist, including the presence of
extrarenal features, kidney function, blood pressure, hema-
turia, proteinuria, biochemical/hematological abnormalities,
imaging, renal histopathology, and results of prior genetic
investigations if already performed. A detailed family history
was recorded to identify the number of at-risk relatives.
The clinically suspected diagnosis and differential diagnoses
were collected at two different time points prior to release of
ES results: (1) the suspected diagnoses by the referring
physician and (2) the suspected diagnoses following review by
the RGC team. Additional details, including diagnostic tests
that may have been performed in the absence of ES, were also
collected. Diagnostic utility for each patient was recorded: we
classified patients as having a “confirmation of diagnosis”
when the referral diagnosis was concordant, and “clarification
of diagnosis” when ES eliminated diagnostic or inheritance
uncertainty (in cases where the presumed inheritance pattern
was incorrect or unknown, or where there were up to two
possible differential diagnoses listed). Recommendations and
changes to clinical management were recorded by nephrol-
ogists at return of ES results and at three months following
results.
Exome sequencing and variant analysis
Genomic DNA was isolated from blood and saliva samples.
ES was performed in a clinically accredited laboratory
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(Victorian Clinical Genetics Services, Melbourne). Coding
regions were enriched using the CREv2 exome capture kit
(Agilent). Sequencing was performed on HiSeq 4000
(Illumina) to an average target depth of 100×. Data were
analyzed using an in-house validated version of Cpipe,21
followed by variant filtering and analysis using an in-house
adapted version of the Leiden Open Variation Database
(LOVD).22,23 A variant prioritization meeting was attended by
a laboratory scientist, clinical geneticists, genetic counselors,
and nephrologists. Data were analyzed only for variants in
conditions relating to patient phenotype following a tiered
approach. Initially, variants in genes associated with the
patient’s specific disease category (e.g., glomerular disease)
were evaluated. If no variants were identified, analysis was
expanded to a broader group of 336 known kidney disease
genes.24 These are listed in Supplementary table S1. Where
clinically relevant (in patients with extrarenal manifestations
suggestive of a syndromic diagnosis), a virtual panel of ~4000
genes known to cause Mendelian disorders (Mendeliome) was
used.25 Standard turnaround time for ES was six months.
Nine patients had had rapid ES processing based on clinical
need, with results available within 21 days. Variants were
classified according to the current American College of
Medical Genetics and Genomics (ACMG) guidelines for
clinical sequencing interpretation.26,27 Variant and phenoty-
pic data were reviewed at a genomics MDT to reach
consensus on variant and case-level interpretation prior to
reporting. Segregation was pursued in cases where the
additional information would alter classification of the
variant.
Outcomes
The primary outcome was the ES diagnostic yield. Molecular
diagnosis was compared with suspected clinical diagnosis at
referral and following RGC assessment. The diagnostic yield
was compared between clinical diagnostic subgroups. The
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Fig. 1 Workflow of the multidisciplinary renal genetics clinic (RGC), from recruitment to result return. Referral received by nephrologist involved
in multidisciplinary RGC. Triage of referral by multidisciplinary team (MDT) consisting of nephrologist/s, clinical geneticist, and genetic counselor. Patient
attends for clinic appointment for clinical review, pretest genetic counseling, and consent. Sample collected at local hospital. Genomic data isolated from
blood and saliva samples. Clinically accredited genomic sequencing performed. Initial computational bioinformatics analysis. Variant prioritization meeting
to prioritize variants for assessment, using a tiered approach, attended by a senior medical genomic scientist, clinical geneticists, lead nephrologist, referring
nephrologist from RGC, and genetic counselors. Variant curation as per American College of Medical Genetics and Genomics (ACMG) guidelines. Review of
variant and phenotypic data by MDT of laboratory scientists, clinical geneticists, nephrologists from the RGC and genetic counselors to reach consensus prior
to reporting and ensure that genotype is concordant with phenotype. Patient attends clinic appointment for return of results with post-test genetic
counseling, with segregation encouraged (where appropriate), suitable patients flagged for recruitment into research. *See “Materials and Methods” for
details, including outlined of tiered approach to testing.
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secondary outcome was diagnostic and clinical utility of ES.
Only ES diagnoses that explained the renal phenotype
contributed to the diagnostic yield.
Statistical analysis
Baseline characteristics were expressed as frequencies (n, %)
and medians (range), as dictated by the data type. Chi-
squared and Fisher’s exact tests (FET) were performed to
compare receiving a positive ES diagnosis and various clinical
characteristics. Multivariable logistic regression was per-
formed to identify baseline clinical characteristics associated
with a diagnostic result. Candidate explanatory variables were
identified from a review of the literature. The final multi-
variable model included all biologically plausible variables
that were robustly collected. Prespecified first-order interac-
tion terms between covariates were examined. Linearity
assumptions were validated by dividing continuous data into
quartiles and fitting as categorical variables. Data were
analyzed using Stata 15.1 (College Station, TX). Two-sided
p values < 0.05 were considered statistically significant.
RESULTS
A total of 225 probands met our inclusion criteria; 21 were
excluded as they declined to participate, withdrew consent,
did not provide a sample for analysis, or obtained a diagnosis
via CMA and did not proceed to ES (Fig. 2). ES was
performed in 204 patients (81 pediatric and 123 adults). Most
patients (147/204) had CMA performed prior to ES, which
was uninformative. Few patients had other forms of genetic
testing prior to the study (five patients had single-gene testing
and four patients had panel testing, all of which were also
uninformative). One patient (P132) had a diagnostic CMA
that was performed concurrently to ES (Supplementary
table S5). The median age at the time of recruitment was
28.5 years (range 1 month–72 years). The median age at first
presentation to nephrology was 16 years (range 0 months–64
years). A total of 138 (68%) had self-declared Caucasian
ethnicity, consanguinity was reported in 11 families (5%), and
103 patients (50%) had a family history of renal disease.
Clinical characteristics of this cohort are provided in Table 1.
At least one of the three major inclusion criteria (family
history of renal disease, presentation of renal disease in
childhood, or extrarenal manifestations) was present in 182/
204 (89%). ES analysis was limited to genes known to cause
GKD (Supplementary table S1) for 182 patients and
Mendeliome analysis was performed in 22 patients. The
median time from ES request to result report was 6 months
(range 10 days to 15.8 months) and the median time from
referral to review in the RGC was 2.4 months (range:
0 months to 16.9 months).
Genomic findings and diagnostic yield
A molecular diagnosis was obtained in 80 of the 204 (39%)
patients (Table 2 and Supplementary table S2). All variants
have been deposited into ClinVar28 (accession numbers
SCV001427100–SCV001427205). Of the 35 monogenic
225 adults who were referred
between Jul 2017-Sep 2018 and had
a suspected monogenic cause of
kidney disease were approached
11 declined to participate
9 withdrew consent/did not provide a
sample for analysis
1 did not require ES due to diagnosis
on CMA
73 patients had a negative result51 patients had a clinically relevant
variant of uncertain significance80 patients had a positive result
204 patients were included and
underwent ES
Adults: 123 patients
Children: 81 patients
Diagnostic Utility:
27 patients (34%) had their
diagnosis confirmed
22 patients (28%) had their
diagnosis clarified
31 patients (39%) had their
diagnosis reclassified
Fig. 2 Flowchart of recruitment and results. CMA chromosomal microarray, ES exome sequencing.
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disorders identified, pathogenic and likely pathogenic variants
in seven genes accounted for 50 of the 81 genetic diagnoses
(one patient had two genetic diagnoses). These included
COL4A3 (n= 6), COL4A4 (n= 9), COL4A5 (n= 11) asso-
ciated with Alport syndrome–related nephropathy; HNF1B
(n= 5) associated with renal cysts and diabetes syndrome
(RCAD); PKD1 (n= 9) and PKD2 (n= 1) associated with
ADPKD; and PKHD1 (n= 9) associated with autosomal
recessive polycystic kidney disease (ARPKD) (Supplementary
figure 1). In five patients with two heterozygous variants
found in autosomal recessive genes, it was not possible to
confirm the variants were in trans within the study timeframe
(supplementary table S2). The variants were assumed to be in
trans when there was a clear genotype–phenotype correlation
and patients were counseled as to the caveats of diagnosis.
In addition, we identified potentially clinically relevant
variants of uncertain significance (VUS) that did not meet
criteria to be reported as likely pathogenic or pathogenic in 52
patients (25%) (Supplementary table S3). All VUS were not
considered to be clinically actionable and patients were
counseled accordingly. In these cases, a letter was sent to the
patient’s treating nephrologist, encouraging them to refer to
the RGC in 2–3 years, for consideration of genomic data
reanalysis.
Clinical predictors of positive ES diagnosis for kidney
disease
The diagnostic yield of ES was higher in the pediatric group,
with 38/81 (47%) children compared with 42/123 (34%)
adults receiving a molecular diagnosis (χ2= 3.34, p= 0.07).
Patients with disease onset in childhood had a higher
diagnostic yield compared with those who presented in
adulthood (56/110= 51% versus 24/94= 26%, (χ2= 13.69,
p= 0 < 0.001) regardless of age at recruitment.
The diagnostic yield of ES differed by diagnostic subgroup
(p < 0.001, FET), being highest in those with tubulopathy (11/
18 [61%)]), Alport syndrome (24/43 [63%]), and cystic kidney
disease (31/65 [48%]). A molecular diagnosis was reported in
3/14 (21%) with syndromic CAKUT, 7/39 (18%) with
nephrotic syndrome, and 4/14 (29%) with nephropathy
attributed to other causes. No patients with a clinical
diagnosis of a complement disorder (n= 6) or nephropathy
of unknown origin (n= 5) received a genomic diagnosis
(Table 3). In 70/80 patients receiving an ES diagnosis (88%),
the diagnostic variants were identified within the virtual gene
panel assigned based on the referral clinical diagnosis group
(e.g., glomerular renal disease), and the remainder of the
diagnoses (10/80, 12%) were obtained from expanded
analysis.
Table 1 Patient cohort clinical characteristics.
Total (n= 204)
Characteristic Number of patients (%)
Age at study entry, median
(range)
28.5 years (1 month–72 years)
Age at study entry
0–17 years 81 (39.7)
≥18 years 123 (60.3)
Age at first presentation to
nephrology, median
(range)
16 years (0 months–64 years)
Age at first presentation to nephrology
0–17 years 110 (53.9)
≥18 years 94 (46.1)
Sex
Male 91 (44.6)
Female 113 (55.4)
Ethnicity
Caucasian 138 (67.7)
Asian 27 (13.2)
North African/Middle
Eastern
18 (8.8)
Other/unknowna 21 (10.3)
CKD stagec (category)
1–2 124 (60.8)
3–4 57 (27.9)
5 5 (2.5)
5D (dialysis) 18 (8.8)
Current transplantb 29 (14.2)
Parental consanguinity
(self-reported)
11 (5.4)
Family history of renal
disease
117 (57.4)
Transplantb 31 (15.2)
Extrarenal manifestations 53 (26.0)
Dialysis 18 (8.8)
a3 patients had unknown ethnicity, other ethnicity included 3 Maori/Pacific Islan-
der, 1 Aboriginal/Torres Strait Islander, 5 Sub-Saharan Africa, 9 mixed ethnicity.
b3 additional patients had a failed kidney transplant requiring dialysis (included
in 5D).
cChronic kidney disease (CKD) stage per Kidney Disease: Improving Global out-
comes (KDIGO) guidelines.
Table 2 Diagnostic yield by clinical diagnosis group (defined
a priori).
Clinical
diagnosis
Sequencing
performed
(n= 204)
Diagnostic variant
identified (n= 80)
Diagnostic
yield (%)
Number of patients Percent
Alport 43 24 55.8
CAKUT 14 3 21.4
Complement
abnormality
6 0 0.0
Cystic 65 31 47.7
Nephrotic 39 7 18.0
Tubular
diseases
18 11 61.1
Other 14 4 28.6
Unknown 5 0 0.0
Total 204 80 39.2
CAKUT congenital anomalies of the kidney and urinary tract.
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On multivariable analysis age at first presentation of renal
disease and family history were independent clinical predictors
of ES diagnosis (Supplemental Fig. 2 and Supplementary
table S4). There was no association between female sex, presence
of extrarenal manifestations, or parental consanguinity with a
positive diagnosis. Compared with those with onset of renal
disease after 30 years of age, those with renal disease in infancy
(<1 years; odds ratio [OR] 9.05, 95% confidence interval [CI]
2.90–28.26) or childhood (age 1 to 17 years; OR 2.42, 95% CI
1.21–6.24) were more likely to have a molecular diagnosis on ES
(p < 0.001). Patients with a positive family history of renal disease
in at least one first or second degree relative were more likely to
receive ES diagnosis (OR 2.51, 95% CI 1.21–4.84, p= 0.01).
Diagnostic and clinical utility of ES
When comparing the suspected clinical diagnosis at referral to
RGC in the 80 patients with ES diagnoses, 27 (34%) had their
clinical diagnosis confirmed, 22 (28%) had clarification of their
diagnosis, and 31 (39%) had complete reclassification of their
original diagnosis (Fig. 2, Supplementary table S2). ES diagnosis
had management implications in 47/80 patients [59%]). These
included negating the need for diagnostic renal biopsy in 10/80
(13%), changing surveillance in 35/80 (44%), and changing
treatment plan in 16/80 (20%). Other specific changes to
management were made in 7/80 (9%), which included
facilitating an earlier transplant, preventing invasive investiga-
tions, and informing decision making in pregnancy. Reproduc-
tive counseling was not included as a clinical implication unless
it resulted in a specific outcome. Even in cases with no changes
to management in the proband, the ES result had implications
for the management of family members in 26/33 (79%) cases.
Cascade testing was offered to 40/80 (50%) families and changes
in management were initiated in family members of 23/80
patients with a diagnosis. Table 2 summarizes the clinical utility
of all patients with an ES diagnosis. Details of all diagnostic
genetic variants and their clinical utility are outlined in
Supplementary table S2. In addition, a further five patients in
the study achieved a molecular diagnosis but were not included
in the total diagnostic yield (Supplementary table S5).
ES proved valuable even in cases where a suspected
diagnosis was confirmed or clarified. For example, in 16
patients with suspected hereditary nephritis or Alport
syndrome, ES informed surveillance in all patients (e.g.,
audiology and ophthalmology screening or changed fre-
quency of nephrology review), allowed identification of at-risk
relatives who were subsequently offered genetic testing in 11
families (Table 2), and obviated the need for diagnostic renal
biopsy in 7 patients. In another patient, P137, ES confirmed
the suspected diagnosis of autosomal dominant hypocalciuric
hypercalcemia. This patient had previously undergone para-
thyroidectomy, which would not have occurred if this
diagnosis was known. The patient was provided reassurance
regarding ongoing hypercalcemia postsurgery and her at-risk
child was subsequently referred for biochemical screening.
In 31/80 patients (39%), ES reclassified the clinical diagnosis.
In patient P130, genomic testing revised a longstanding clinical
diagnosis of ADPKD to ARPKD. This diagnosis provided
valuable information with regard to family planning, with
retraction of the previously given 50% recurrence risk. The
patient conceived naturally, and a year later, had an unaffected
child. In P020, ES diagnosed autosomal recessive Alport
syndrome in a child who presented with steroid-resistant
nephrotic syndrome and microscopic hematuria. Renal biopsy
suggested an inherited glomerular basement membrane
abnormality. Following ES result, a recommendation was made
to cease existing cyclosporin treatment, with renin–angiotensin
inhibition, audiology, and ophthalmology surveillance to be
continued; his siblings were referred for cascade testing.
Rapid genomic testing
Nine patients underwent rapid ES, with median time to report
28 days (range 10–49 days). The characteristics and results of
Table 3 Summary of clinical utility in 80 patients with exome sequencing diagnosis.
Clinical diagnosis
Subgroup (number
of ES Dx)
Proband Family Overall
Negated
renal biopsy
Changed
treatment
Changed
surveillance
Other No change Clinical
utility
Cascade
testing
Other Clinical
utility
Clinical
Utility
Number, % Number, %
Alport (24) 9 10 16 0 3 21 (88) 17 2 20 (83) 24 (100)
CAKUT (3) 0 0 1 0 2 1 (33) 1 1 2 (67) 3 (100)
Cystic (31) 0 3 9 5 18 13 (42) 16 13 26 (84) 28 (90)
Nephrotic (7) 0 0 4 0 3 4 (57) 4 2 6 (86) 6 (86)
Tubular (11) 0 2 3 1 6 5 (45) 1 4 4 (73) 8 (73)
Other (4) 1 1 2 1 1 3 (75) 1 1 2 (36) 4 (100)
Total (80) 10 16 35 7 33 47 (59) 40 23 60 (75) 73 (91)
Other: other specific patient implications, such as facilitating earlier transplant in the patient, preventing other invasive investigations, informed decision making in preg-
nancy. Reproductive counseling was not included unless it resulted in a specific outcome. No change: no change in management of the proband. Family implications:
changes to management in families of proband other than cascade testing included carrier testing in families for reproductive purposes, donor selection for facilitating
transplant in family members where patient themselves was already transplanted, when autosomal dominant condition was segregated and found to be de novo, allow-
ing family members to be released from screening/cascade testing/surveillance, biochemical screening in family members (when deemed more appropriate than cascade
testing by the clinical team). Overall clinical utility: includes total number of patients with clinical utility demonstrated in themselves or their family. Cascade testing: num-
ber of families (not individuals) who were offered cascade testing.
CAKUT congenital anomalies of the kidney and urinary tract, ES exome sequencing.
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this group are outlined in Supplementary table S6. In five
cases, rapid ES resulted in direct changes to clinical manage-
ment. For example, a seven-year-old boy who was initially
thought to have Dent disease developed heavy proteinuria and
a renal biopsy was planned for suspected Alport syndrome.
Rapid ES confirmed X-linked recessive (XLR) Dent disease,
negating the need for renal biopsy and audiology and
ophthalmology surveillance. Cascade genetic testing was
subsequently offered for his two brothers. In another patient
with features of an undiagnosed ciliopathy, rapid ES
diagnosed autosomal recessive short-rib thoracic dysplasia
10 with or without polydactyly (OMIM 615630). This not
only provided important prognostic information including an
explanation for the multisystem nature of the disease, but it
also clarified that her father was at low risk of the same
condition, enabling live kidney donation.
DISCUSSION
In this large, prospective multicenter study, we comprehen-
sively evaluated the diagnostic and clinical utility of ES in
adults and children with suspected genetic CKD. Our cohort
was ethnically diverse, and diagnostic variants were detected
within all major clinical diagnostic subcategories (such as
Alport, nephrotic syndrome, tubulopathies, and cystic kidney
disease). By using a multidisciplinary approach in concert
with clinical ES, we detected a monogenic cause of kidney
disease in 39% of patients. Our diagnostic yield in adults
(34%) is significantly higher than the recently published
cohort by Groopman et al.,3 which likely reflects the
differences in patient selection, as patients in this study were
assessed as having possible GKD following MDT assessment.
Our yield is comparable with other published cohorts with
suspected GKD,13,29,30 apart from the retrospective study by
Thomas et al.,14 which found a diagnosis in 26/43 (60%)
patients who underwent genetic testing. The lower diagnostic
yield in our cohort is likely due to several reasons. First, as our
study focus was on ES, we did not include patients who
presented to RGC for cascade testing in the context of an
established genetic diagnosis in the family; these patients were
more suitable for Sanger sequencing. Second, the study by
Thomas et al. included a large proportion of patients with
clinically suspected ADPKD. ADPKD is the leading cause of
Mendelian kidney disease and can be confidently diagnosed
clinically.31 We did not intend to include those patients with
an already established ADPKD diagnosis and hence patients
with a phenotype and family history highly suggestive of
typical ADPKD were excluded from our cohort. Finally, our
cohort was much larger and more diverse, and did not include
multiple patients from the same pedigree.
This is the only prospective study to date that provides
detailed evaluation of both diagnostic and clinical utility of ES
in kidney disease patients. Apart from the small retrospective
study by Thomas et al., no other studies have evaluated the
actual clinical implications of ES for patient and family
management. While some studies have attempted to infer the
potential clinical implications of a genomic diagnosis on
patients,2,13 they did not collect detailed information to
measure the actual implications for each individual patient.
ES altered the diagnosis in a substantial proportion of
individuals in our cohort (39%), compared with recently
published studies.13,16 Even in cases where ES confirmed a
clinical diagnosis, this proved valuable by providing a
definitive diagnosis and information on inheritance pattern,
thereby preventing further investigations and enabling
appropriate screening and genetic counseling of family
members. Patients with a revised diagnosis following ES
experienced even more significant changes in clinical manage-
ment, including avoidance of immunosuppression, avoidance
of renal biopsy, appropriate medical surveillance, cascade
testing and screening among family members, and informing
transplant and reproductive decisions.
One of the most important benefits of ES in the renal
setting may be avoiding unnecessary and invasive diagnostic
investigations such as renal biopsy, which carry considerable
risk and cost, particularly in the pediatric population.32,33 In
our study, a planned renal biopsy was no longer required in
ten patients who received a molecular genetic diagnosis.
Genomic testing has already been shown to be cost-effective
in other specialties, such as pediatric acute care.34 During this
study period, the cost of ES was approximately AU$2300, or
US$1600 (including patient review, sequencing, and analysis
of up to 100 genes). The cost of a biopsy varies, but an
uncomplicated renal biopsy is approximately AU$1600 (US
$1100) per adult and AU$5300 (US$3700) per child at our
institution. Therefore, a timely genomic diagnosis has the
potential to be cost-effective, particularly in those patients
where biopsies are no longer required. In some cases, the
standard turnaround time (TAT) for genomic results achieved
during this study of six months is likely to be too long. For
this reason, we performed rapid sequencing (with a result
available within a week if required) in those patients where it
was predicted to have immediate clinical implications. This
TAT had already improved to 3 months by the end of the
study, mainly due to improved experience among clinicians,
resulting in increased efficiency at variant prioritization
meetings and MDT meetings, and is likely to improve further
as genomic testing practices become more streamlined.
Our study provides data to assist with prioritizing patients
for genomic testing, particularly in resource-limited health
systems. In our cohort, age at presentation of renal disease
and positive family history were independent clinical
predictors of ES diagnosis. Extrarenal features, which have
been recognized as risk factors for genetic disease in previous
studies,29 were not significantly associated with ES diagnosis
in this cohort. Most patients with extrarenal features (40/53)
presented in childhood, hence it is possible that in this cohort
childhood onset was a proxy for extrarenal manifestations.
There was no association with an ES diagnosis and parental
consanguinity, although it is possible that our study may be
underpowered to detect a difference, due to the small number
of patients (n= 11) with this history. Patients with cystic,
Alport, and tubulopathy phenotypes had the highest
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diagnostic yield, suggesting that ES is a particularly useful
diagnostic test in these groups. When interpreting the
diagnostic yield, it is important to note that all our patients
were referred for clinical rather than for research-based
testing. Therefore, our results are pragmatic and are more
likely to be replicated in clinical practice compared with
studies that conducted research-based testing. We also
recognize that the diagnostic yield may improve in future
with reanalysis of ES data,35 and this has recently been funded
by our health-care system. Compared with the few other
studies that have applied genomic testing to similar
cohorts,2,13,30 our study collected detailed phenotypic infor-
mation, including a specific a priori clinical diagnosis and all
prior investigations. This allowed for a more accurate
determination of phenotype–genotype correlation. Further-
more, to minimize bias, the physicians who recorded
implications for clinical care were those directly involved
with each patient, rather than the main study investigators.
Many barriers to effective implementation of genomics in
nephrology and in other specialties have been described,36
including physician knowledge gaps surrounding genetics.37
Knowledge gaps among nephrologists surrounding assess-
ment of patients with GKD, testing processes, patient consent,
and counseling were also an important implementation
challenge in our study. None of the nephrologists involved
in the genetics clinics in this study had formal genetics
training, although three had additional research and clinical
experience in this area. This challenge was foreseen prior to
study commencement, and the multidisciplinary RGC model,
which allowed support from a clinical geneticist and genetic
counselor in reviewing all patients, was used to address this.38
Our study has limitations. We did not consider the possible
contribution of digenic inheritance or susceptibility alleles to
the diagnostic yield in this cohort. ES has limited utility in
detecting structural, mitochondrial, and noncoding variants.39
Clinicians were encouraged to perform CMA prior to ES in all
patients. As microarray is performed routinely as part of the
initial diagnostic work-up of patients with suspected genetic
conditions, we were unable to quantify the contribution of
CNVs to the diagnostic yield. One particular concern
regarding the use of ES as a testing modality in renal patients
is the effect of pseudogenes on the ability to reliably detect
PKD1 variants.40 Due to this limitation, we did not include
patients who had a clinical diagnosis of ADPKD. Despite
these concerns, ES detected PKD1 variants in nine patients,
highlighting the ability of ES to distinguish between cystic
kidney disease phenocopies. In addition, we were unable to
quantify the contribution to diagnostic yield of variable
number tandem repeats (VNTRs) such as the MUC1 VNTR
associated with medullary cystic renal disease, as VNTRs are
challenging to identify through ES.41 Some of these technical
limitations are likely be overcome in the future as genome
sequencing becomes more widely established as the preferred
testing modality in the clinical setting.
Although we collected a considerable amount of phenotypic
data for each patient in the study, most of the clinical
phenotype data was collected at study enrollment and not at
onset of renal disease, meaning the age of onset of renal
disease may be inaccurate, particularly in adult patients. For
the same reasons, although we were able to see trends in
diagnostic clinical groups, analyzing specific phenotypic
features (such as hematuria and proteinuria) as clinical
predictors of ES diagnosis was not possible. We also recognize
the high diagnostic yield is due to selecting those patients who
are most likely to have GKD as determined by MDT
discussion, thereby limiting generalization to other service
delivery models. Given the finite resources in most settings,
the purpose of this study was to determine whether ES
demonstrates diagnostic and clinical utility in selected
patients, and to provide insight into clinical characteristics
associated with higher yield to help clinicians prioritize
patients for testing. Furthermore, careful assessment of
patients and testing those who are more likely to benefit
represents the current clinical approach in our health-care
system. Finally, although we were able to determine
immediate changes in clinical care following ES, long term
clinical outcome data could not be captured in the study
timeframe, and in most cases, these clinical decisions were at
the discretion of the treating nephrologist.
Conclusions
ES identified a molecular diagnosis in almost 40% of patients
referred for testing in a multidisciplinary RGC context. Our
results confirm that in a pragmatic pediatric and adult cohort
with suspected monogenic kidney disease, ES was not only
valuable for establishing a specific molecular diagnosis, but
also demonstrated substantial quantifiable impacts on clinical
management. These findings, including the predictors of
positive diagnosis, motivate further examination and valida-
tion in other cohorts. Further prospective studies evaluating
the cost-effectiveness and implementation aspects of genomic
testing in this population are required to improve access to
testing for those most likely to benefit.
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